tiprankstipranks
Advertisement
Advertisement
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
PremiumCompany AnnouncementsKyverna Therapeutics Appoints Chief Commercial Officer for Growth
2M ago
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
2M ago
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
Premium
Ratings
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
2M ago
Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel
PremiumThe FlyKyverna Therapeutics presents longer-term Phase 2 data for Miv-cel
3M ago
Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis
Premium
Company Announcements
Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis
3M ago
Kyverna Therapeutics files $300M mixed securities shelf
Premium
The Fly
Kyverna Therapeutics files $300M mixed securities shelf
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100